Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer

CVRx (NASDAQ: CVRX) minority shareholder Jorey Chernett, founder of Pointillist Family Office and owner of more than 5.5% of CVRx shares, delivered a letter to the CVRx board on August 24, 2026.

Rhea-AI Summary

CVRx (NASDAQ: CVRX) minority shareholder Jorey Chernett, founder of Pointillist Family Office and owner of more than 5.5% of CVRx shares, delivered a letter to the CVRx board on August 24, 2026. He urges the board to begin an immediate, formal process to sell the company to a strategic acquirer, highlighting the Barostim product as a key asset.

Chernett asks the board to retain an independent financial advisor, prioritize a sale within a broader strategic review, cut executive compensation and G&A, suspend incremental standalone spending, and publicly commit to a defined process and timeline.

News Explained

The Aug. 24 release is a request from shareholder Jorey Chernett, not an announced sale process or completed transaction: it provides no buyer, consideration, cash receipt, or ownership change for existing CVRx holders.

Argus Aug 24 session 22 alerts

+10.92% close to close 30.0x rel. volume Open Argus

Details

Market move: CVRX +10.92% in the Aug 24 session. strategic sale process

+10.7% Peak in 1 hr 3 min

$87.58M Market Cap

On Aug 24, the day this news came out, CVRX closed 10.92% above the previous close. Argus tracked a peak move of +10.7% during that session. Our momentum scanner recorded 22 alerts for this stock that day. Relative volume reached 30.0x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 24 session.

Key Figures

Ownership stake: More than 5.5% of outstanding shares Accretion timeline: Twelve months

Ownership stake

More than 5.5% of outstanding shares

Jorey Chernett's reported CVRx ownership

Accretion timeline

Twelve months

Claimed timeframe for a strategic acquirer to achieve accretion

Historical Context

5 past events · Latest: Aug 11

5 events

1. Aug 11

   Sales leadership transition

   24h Move

   +9.9%

   Chief revenue officer departed amid revised commercial outlook and execution concerns

2. Aug 06

   Second-quarter earnings

   24h Move

   -59.8%

   Quarterly results included a net loss, European decline, and lowered commercial outlook

3. Jul 28

   Conference presentation

   24h Move

   +1.4%

   Management scheduled a presentation at Canaccord Genuity's annual growth conference

4. Jul 23

   Earnings date announcement

   24h Move

   -3.1%

   Company scheduled second-quarter results and an accompanying conference call

5. Jun 09

   CFO transition

   24h Move

   -3.7%

   CFO announced resignation and company began searching for a successor

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

beneficial owner, g&a expense, neuromodulation therapy

3 terms

beneficial owner regulatory

"beneficial owner of more than 5.5% of the outstanding shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

g&a expense financial

"cut executive compensation and G&A expense"

General and administrative (G&A) expense is the category of operating costs a company incurs to run its day-to-day business that are not tied to making products or delivering services. Examples include executive and back-office salaries, rent, utilities, accounting and legal fees, office supplies, and insurance. Investors watch G&A because it reduces reported profits and cash flow and helps show how efficiently a company manages its overhead—like a household’s recurring bills that keep the home functioning.

neuromodulation therapy medical

"the only approved neuromodulation therapy for heart failure"

Neuromodulation therapy uses medical devices or targeted drugs to change how nerves or brain circuits fire, often by sending electrical pulses, delivering chemicals, or using other focused stimuli; think of it as a dimmer switch that raises or lowers nerve activity to relieve symptoms. It matters to investors because device approvals, clinical trial results, reimbursement rules, and wider adoption determine revenue potential and risk for companies that develop, manufacture, or sell these treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Delivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market Position

BLOOMFIELD HILLS, Mich., Aug. 24, 2026 /PRNewswire/ -- Jorey Chernett, Founder of Pointillist Family Office and beneficial owner of more than 5.5% of the outstanding shares of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRx), today delivered a letter to the CVRx Board of Directors (the "Board"), urging it to launch an immediate and formal process to sell the Company to a strategic acquirer.

In the letter, Mr. Chernett outlines why CVRx, through its Barostim product, would be uniquely valuable to a large medical device company. A sale of CVRx can be accretive to such an acquirer within twelve months, and would enable CVRx shareholders to realize immediate value far superior to what the Company can plausibly deliver on a standalone basis.

As a result, Mr. Chernett calls on the Board to:

1. Immediately retain an independent financial advisor and initiate a comprehensive review of strategic alternatives, with a sale of the Company as the priority outcome;
2. Aggressively cut executive compensation and G&A expense, as well as suspend incremental standalone spending commitments while that review is conducted; and
3. Publicly commit to a comprehensive process and clear timeline. A sale process launched now, while the Company retains cash, momentum in the field, and the strategic scarcity of the only approved neuromodulation therapy for heart failure, will command a far better outcome for shareholders than one forced upon the Company as a result of a depleted cash balance a year from now. The Board must move with urgency instead of waiting to be rescued; time is of the essence.

The full text of the letter is available HERE.

Media Contact:
ASC Advisors
Taylor Ingraham / Max Rayden
tingraham@ascadvisors.com / mrayden@ascadvisors.com
203 992 1230

View original content to download multimedia:https://www.prnewswire.com/news-releases/jorey-chernett-owner-of-more-than-5-5-of-outstanding-shares-of-cvrx-calls-on-board-to-begin-immediate-process-to-pursue-sale-of-the-company-to-a-strategic-acquirer-302858259.html

SOURCE Jorey Chernett

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did shareholder Jorey Chernett request from the CVRx (NASDAQ: CVRX) board on August 24, 2026?

Chernett requested that the CVRx board immediately launch a formal process to sell the company to a strategic acquirer. According to Jorey Chernett, this should include a comprehensive review of strategic alternatives with a sale as the priority outcome and a clearly communicated process and timeline.

Who is Jorey Chernett and how much CVRx (CVRX) stock does he own?

Jorey Chernett is the founder of Pointillist Family Office and a significant CVRx shareholder. According to Jorey Chernett, he is the beneficial owner of more than 5.5% of the outstanding shares of CVRx, giving him a sizeable minority position in the company.

What strategic steps does Jorey Chernett propose for CVRx (CVRX) in his August 24, 2026 letter?

Chernett proposes that CVRx immediately retain an independent financial advisor and conduct a full strategic review focused on a sale. According to Jorey Chernett, the board should also cut executive compensation and G&A, suspend incremental standalone spending, and publicly commit to a comprehensive process and timeline.

How does the Barostim product influence Jorey Chernett’s call for a CVRx (CVRX) sale?

Barostim is highlighted by Chernett as central to CVRx’s appeal for a larger medical device company. According to Jorey Chernett, Barostim’s market position could be better leveraged by a buyer with established infrastructure, potentially enhancing the product’s reach and commercial performance.

Did the CVRx (CVRX) board agree to pursue a sale after Jorey Chernett’s August 24, 2026 letter?

The announcement only states that Chernett delivered a letter urging a sale; it does not describe any board response. According to Jorey Chernett, he called for a strategic review and sale process, but no board decision or action is reported in this release.